

Lung Committee

Leadership

Chair: Jhanelle E. Gray, MD
 Vice-Chair: Roy S. Herbst, MD, PhD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Mary Redman, PhD
 Yingqi Zhao, PhD
 Katherine Minichiello, MS
 Jieling Miao, MS
 James Moon, MS
 Lu Qian, MS

Scientific Leadership
 Translational Medicine:
 Biology/Pathology: Philip C. Mack, PhD
 Fred R. Hirsch, MD, PhD
 Ignacio I. Wistuba MD
 Imaging: Chadwick L. Wright MD, PhD
 Myrna C. Godoy, MD, PhD
 Radiation Oncology: TBD
 Surgery: Wayne L. Hofstetter, MD

Subcommittee Chairs:
 Early Stage Disease: Wayne L. Hofstetter, MD
 Raymond Osarogiagbon, MD
 Locally Advanced Disease: Shirish Gadgeel, MD (Early Therapeutics)
 Metastatic Disease: Ross Camidge, MD
 Karen Reckamp, MD
 Community Engagement: Paul J. Hesketh, MD
 Suzanne Cole, MD

Designates
 Cancer Control Liaison: Gary E. Goodman, MD
 DEI Champion: Lucy Gansauer, MSN, RN, OCN, CCRP
 Veterans Affairs: Chao H. Huang, MD
 Cheryl M. Czerlanis, MD
 Data Coordinators: Louise Highleyman
 Larry Kaye
 Pasarlai Ahmadzai
 Amy Johnson
 Clinical Research Project Manager: TBD
 Oncology Research Professionals:
 CRA: TBD
 Nurses: Rosalie Zablocki, RN
 Patient Advocate: Judy Johnson, MBA
 Pharmaceutical Science: Joyce Lee, PharmD
 Kimberly McConnell, PharmD
 Protocol Project Managers: TBD

..... Melissa Biddle (Lung-MAP)
 Jennifer Beeler (Lung-MAP)
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Friday, May 12, 2023 3:00 pm - 6:00 pm
 Room: Seacliff B-D (Bay Level)

Agenda

3:00 - 3:10 pm General Update: Jhanelle E. Gray, MD
 3:10 - 3:20 pm Patient Advocate Update: Judy Johnson, MBA
 3:20 - 3:30 pm Thoracic Surgery Session: Eric Toloza, MD, PhD
 3:30 - 3:40 pm Thoracic Radiation Session: Megan Daly, MD
 3:40 - 3:50 pm Translational Medicine Session: Philip C. Mack, PhD
 3:50 - 4:00 pm Statistical Group: Mary Redman, PhD
 4:00 - 4:10 pm Community Engagement Core: Paul J. Hesketh, MD
 4:10 - 4:20 pm DEI Session: Lucy Gansauer, MSN, RN
 4:20 - 4:30 pm Accrual Enhancement Discussion
 4:30 - 4:50 pm Livingston Lecture Keynote Speaker: Karen Kelly, MD
 CEO-International Association for the Study of Lung Cancer (IASLC)
 Professor Emeritus, University of California, Davis
 4:50 - 4:55 pm S2302, "Project Pragmatica-Lung Trial": Karen Reckamp,
 MD; Activated: 3/6/23; Accrual: 4
 4:55 - 5:25 pm Discussion Panel: S2302 Pragmatica-Lung Trial
 Karen L. Reckamp, MD, Co-Director of the Lung Cancer and Thoracic
 Oncology Program at City of Hope
 Mary Redman, PhD, Lead Statistician, Lung Cancer Committee, SWOG
 Harpreet Singh, MD, Director of the Division of Oncology, FDA
 Shakun Malik, MD, Head of Thoracic Cancer Therapeutics, NCI CTEP
 Ellen V. Sigal, PhD, Chairperson and Founder, Friends of Cancer Research
 Dan Carrizosa, MD, Lung Community Engagement Committee, SWOG
 5:25 - 6:00 pm Thoracic Medical Oncology Session: Jhanelle Gray, MD
Lung-MAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies
 and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer

Lung Committee

(Lung-MAP Screening Study).” Drs. Karen Reckamp and David Gandara (SWOG). Activated: 1/28/19; Accrual: 2992

S1900E, “A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study).” Drs. Sukhmani Padda (SWOG) and David Gerber (ECOG). Activated: 4/2/21; Accrual: 87

S1900E, “A Phase II Study of Selpercatinib, Carboplatin And Pemetrexed In Patients With RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer (Lung-MAP Sub-Study).” Dr. Yasir Elamin (SWOG) and Dr. Jhanelle Gray (SWOG). Accrual Goal: 74

S1827, “MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK).” Dr. Chad Rusthoven. Activated: 1/10/20; Accrual:139

S1933, “A Pilot Trial of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status.” Dr. Raid Aljumaily. Activated: 6/15/20; Accrual: 28

S1914, “A Randomized Phase III trial of Induction/Consolidation Atezolizumab +SBRT versus SBRT Alone in High risk, Early Stage NSCLC.” Dr. Megan Daly. Activated: 3/25/20; Accrual: 186

EA5163/S1709, “INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Post-progression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis.” Dr. Anne Chiang. Activated: 2/28/19. Accrual: 488 total; 64 SWOG.

6:00 pm Closing Remarks and Adjourn

Active Studies

LUNGMAP, “A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study).” Drs. Borghaei, Reckamp, Gandara, et al. Activated: 1/28/19.

S1800D, “A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study).” Drs. Wrangle and Husain. Activated: 2/15/22.

S1900E, “A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study).” Drs. Padda and Gerber. Activated: 4/2/21.

S1900E, “A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study).” Drs. Gray and Elamin. Activated: 7/25/22.

S1701, “A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma.” Drs. Tsao and Koczywas. Activated: 8/9/18.

S1827, “MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK).” Drs. Rusthoven, Brown, Wefel, et al. Activated: 1/10/20.

S1914, “A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC.” Drs. Daly, Simone, Kelly, et al. Activated: 3/25/20.

S1933, “A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status.” Drs. Aljumaily, Mitin, and Wozniak. Activated: 6/15/20.

CTSU/EA5163/S1709, “INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis.” Dr. Chiang. Activated: 2/28/19.

CTSU/A081801, “Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO).” Dr. Gray. Activated: 6/3/20.

CTSU/A151216, “Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST).” Dr. Gandara. Activated: 8/18/14.

CTSU/E4512, “A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.” Dr. Li. Activated: 8/18/14.

Lung Committee

CTSU/EA5181, "Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC." Dr. Harkenrider. Activated: 4/9/20.

CTSU/EA5182, "Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)." Dr. Goldberg. Activated:10/22/20.

CTSU/EA5191, "A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC." Dr. Massarelli. Activated: 5/22/20.

CTSU/NRG-LU002, "Maintenance Systemic Therapy versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial." Dr. Gomez. Activated: 4/7/17; Temporary closure: 11/12/21.

CTSU/NRG-LU005, "Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab." Dr. Hsu. Activated: 5/28/19; Closed to US and Canadian sites 6/23/22.

CTSU/NRG-LU007, "Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial." Dr. Park. Activated: 8/17/20.

Closed Studies

CTSU/NRG-CC003, "Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer." Dr. Gaspar. Activated: 12/7/15; Temporary closure: 5/28/20; Re-activated: 7/27/20; Permanent closure: 6/21/22.

S1800A, "A Phase II Randomized Study of Ramucirumab Plus Pembrolizumab (MK-3475) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Reckamp and Dragnev. Activated: 5/17/19. Permanently closed: 10/20/20.

S1900A, "A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Riess and Wheatley-Price. Activated: 1/28/19. Permanently closed: 2/2/21.

S1900B, "A Phase II Study of Selpercatinib (LOXO-292) in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Elamin and Gray. Activated: 2/10/20. Permanently closed: 5/1/21.

S1900C, "A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)." Drs. Skoulidis and Suga. Activated: 1/16/20. Permanently closed: 12/18/20.

S1929, "Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Drs. Karim, Reckamp, Gay, et al. Activated: 6/15/20; Step 1 Registration Permanently Closed 8/15/22; Step 2 Permanently Closed 10/15/22.

S1934, "NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer." Drs. Osarogiagbon, Huang, Decker, et al. Activated: 9/9/21; Temporary closure: 11/5/21; Re-activated: 2/15/22; Permanently closed 3/1/23.

NCI-Approved Concepts

S1900G, "A Randomized Phase II Study of INC280 (capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Goldberg and Camidge.

S1900I, "A Randomized Phase II study of Mobocertinib (TAK-788) with or without Ramucirumab in Participants with Previously Treated EGFR Exon 20 Insertion Non-Small-Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Doroshov and Patel.

S1900J, "A Phase II Study of Amivantamab in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Rolfo and Gadjeel.

S1900K, "A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Paik and Le.

S2302, "PROJECT PRAGMATICA: A Prospective Randomized Study of Ramucirumab (NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-small Cell Lung Cancer in Standard Practice." Drs. Reckamp and Dragnev.

Lung Committee

Accrual from trial opening through 12/31/2022 by Institution and Study

	LUNGMAP	S1701	S1800D	S1827	S1900E	S1914	S1929	S1933	A081801	A082002	A151216
Ascension Providence Hosp - Southfield	13	-	-	-	-	-	3	-	-	-	14
Ascension Via Christi Hosp Wichita	1	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson CC	-	-	-	1	-	-	-	-	1	-	1
Banner U Med Ctr - Tucson	-	-	-	-	-	-	-	-	-	-	7
Baptist Mem Hlth Care/Mid South MU NCORP	34	-	-	-	1	5	2	-	3	-	24
Baylor College of Medicine/Dan L Duncan CCC	-	-	-	1	-	-	-	-	-	-	-
Boston Med Ctr	-	-	-	4	-	-	-	-	-	-	3
CWRU Case CCC LAPS	11	-	-	-	2	-	-	-	6	-	50
Ca Res Consort of W Mich NCORP	3	-	-	-	-	2	-	-	-	-	1
Ca Res for the Ozarks NCORP	32	-	3	-	-	-	2	3	-	-	3
Ca Res of Wisconsin and N Mich Consort	25	-	2	-	3	-	-	-	-	-	-
Carle CC NCORP	2	1	-	-	-	5	-	-	-	-	-
Cedars-Sinai Med Ctr	13	-	-	-	1	-	-	-	-	-	-
City of Hope CCC	5	1	-	1	-	-	-	-	-	-	5
Columbia U MU NCORP	8	-	-	-	-	-	-	-	-	-	-
Columbus NCORP	26	-	-	3	-	-	-	-	-	-	-
CommonSpirit Hlth Res Inst	44	-	-	-	-	1	2	-	-	-	2
Cotton O'Neil CC / Stormont Vail Hlth	-	-	-	-	-	-	-	-	-	-	3
Dayton NCORP	2	-	-	-	-	-	2	-	1	-	8
Essentia Hlth NCORP	16	-	2	-	-	2	-	-	-	-	-
Fred Hutchinson Ca Res Ctr LAPS	4	-	-	-	-	-	-	-	-	-	15
Georgia Cares MU NCORP	6	-	-	1	-	2	3	1	-	-	-
Georgia NCORP	58	-	3	2	1	3	-	-	-	-	9
Gulf South MU NCORP	16	-	1	1	-	1	1	-	1	-	1
Hawaii MU NCORP	22	-	-	1	-	-	-	-	-	-	-
Heartland Ca Res NCORP	121	-	6	2	4	21	19	2	-	-	-
Henry Ford Hosp	7	-	-	-	-	-	1	-	2	-	29
Houston Methodist Hosp	-	-	-	-	-	-	-	-	-	-	8
Kaiser Permanente NCORP	67	-	3	-	7	2	-	-	2	-	200
Lahey Hosp and Med Ctr	30	-	-	-	-	2	1	2	-	-	30
Loma Linda U Med Ctr	6	-	-	-	-	-	-	-	-	-	9
Loyola U Med Ctr	22	-	1	-	-	-	2	-	-	-	21
Massachusetts Veterans ERIC	48	-	1	2	1	-	-	-	7	-	26
Med U South Carolina MU NCORP	14	-	1	-	1	-	-	-	-	-	-
Michigan Ca Res Consort NCORP	105	-	4	-	6	2	3	-	-	-	-
Moffitt CC	12	2	1	1	1	-	-	-	11	-	83
Montana Ca Consort NCORP	25	-	-	-	1	-	3	1	-	-	-
Mount Sinai Hosp	-	-	-	-	-	8	1	-	-	-	-
NCORP Carolinas (Prisma Hlth NCORP)	15	-	-	-	1	-	-	-	-	-	1
Nevada Ca Res Foundation NCORP	14	-	-	-	-	-	1	-	-	-	-

Lung Committee

Accrual from trial opening through 12/31/2022 by Institution and Study

	LUNGMAP	S1701	S1800D	S1827	S1900E	S1914	S1929	S1933	A081801	A082002	A151216
New Mexico MU NCORP	69	-	-	1	-	6	5	1	-	-	-
Northwell Hlth NCORP	-	-	-	-	-	-	-	-	1	-	3
Northwestern U LAPS	26	1	1	1	-	-	4	-	-	-	-
Oregon Hlth and Science U	7	-	1	-	-	1	-	-	5	-	21
Pacific Ca Res Consort NCORP	15	-	-	-	-	-	3	-	-	-	4
SCL Hlth Saint Joseph Hosp	1	-	-	-	-	1	-	-	1	-	3
Salem Hosp	3	-	-	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	49	-	1	7	-	5	8	-	-	-	-
Sutter Ca Res Consort	24	-	-	-	1	-	-	-	-	-	11
The Don and Sybil Harrington CC	8	-	1	-	-	-	-	-	-	-	-
James Graham Brown CC at U Louisville	-	-	-	-	-	-	-	-	-	-	5
UC Davis CCC LAPS	31	3	6	1	-	9	2	-	-	2	41
UC Irvine Hlth/Chao Family CCC	22	-	-	1	-	1	-	-	-	-	14
UC San Diego Moores CC	11	-	-	-	1	-	-	-	-	-	5
UPMC Hillman CC LAPS	46	-	2	2	5	-	3	2	-	-	-
USC Norris CCC LAPS	-	-	-	2	-	3	-	-	-	-	12
U Arkansas for Med Sciences	11	-	-	-	-	6	-	-	-	-	2
U Cincinnati CC-UC Med Ctr	-	-	-	-	-	-	-	-	-	-	22
U Colorado CC LAPS	10	-	-	1	-	3	2	-	3	-	58
U Kansas CC - MCA Rural MU NCORP	85	-	1	1	1	-	-	-	1	-	28
U Kentucky/Markey CC	47	-	-	1	-	-	-	-	-	-	5
U Michigan CCC LAPS	1	-	-	-	-	-	-	-	-	-	62
U Mississippi Med Ctr	1	-	-	-	-	-	-	-	-	-	26
U Oklahoma Hlth Sciences Ctr LAPS	31	-	-	1	-	1	2	10	-	-	-
U Rochester LAPS	59	-	1	-	6	2	-	-	-	-	-
U Texas HSC at San Antonio	-	-	-	-	-	-	1	-	-	-	-
U Texas MD Anderson CC LAPS	3	6	-	-	-	-	4	-	-	-	2
U Utah - Huntsman Ca Inst LAPS	-	-	-	3	-	2	1	-	-	-	-
Upstate Carolina NCORP	35	-	-	-	-	1	-	-	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	1	-	-	-	-	-	-	-	-	-	1
Western States Ca Res NCORP	2	-	-	-	-	-	-	-	-	-	1
William Beaumont Hosp-Royal Oak	-	-	-	-	-	-	-	-	-	-	2
Wisconsin NCORP	39	-	-	1	-	6	-	-	-	-	-
Yale U - Yale CC LAPS	17	-	-	3	-	1	-	-	4	-	52
ALLIANCE	699	3	12	13	16	20	9	3	-	-	-
CCTG	-	-	-	14	-	-	-	-	-	-	-
ECOG-ACRIN	323	3	4	4	13	13	10	-	-	-	-
NRG	356	1	4	46	6	25	6	1	-	-	-
Total	2,859	21	62	123	79	162	106	26	49	2	933

Lung Committee

Accrual from trial opening through 12/31/2022 by Institution and Study

	A171901	E4512	EA5163	EA5181	EA5182	EA5191	NRGCC003	NRGLU002	NRGLU005	NRGLU006	R1308
Ascension Providence Hosp - Southfield	-	1	2	3	-	1	-	-	-	-	-
Ascension Via Christi Hosp Wichita	-	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson CC	-	-	-	-	-	-	-	-	-	-	-
Banner U Med Ctr - Tucson	-	2	-	7	-	-	-	-	2	-	-
Baptist Mem Hlth Care/Mid South MU NCORP	-	-	1	1	1	-	-	1	1	-	-
Baylor College of Medicine/Dan L Duncan CCC	-	-	-	-	-	-	-	-	4	-	-
Boston Med Ctr	-	-	-	1	-	-	-	-	-	2	-
CWRU Case CCC LAPS	-	-	9	14	1	1	-	-	-	-	-
Ca Res Consort of W Mich NCORP	-	-	-	-	-	-	-	-	-	-	-
Ca Res for the Ozarks NCORP	-	-	-	-	-	-	-	-	-	-	-
Ca Res of Wisconsin and N Mich Consort	-	-	-	-	-	-	-	-	-	-	-
Carle CC NCORP	-	-	-	-	-	-	-	-	-	-	-
Cedars-Sinai Med Ctr	-	-	-	-	-	-	-	-	-	-	-
City of Hope CCC	-	-	-	-	-	-	-	-	-	-	-
Columbia U MU NCORP	-	-	-	-	-	-	-	-	-	-	-
Columbus NCORP	-	-	-	-	-	-	-	-	-	-	-
CommonSpirit Hlth Res Inst	-	-	-	-	-	-	-	-	-	-	-
Cotton O'Neil CC / Stormont Vail Hlth	-	-	-	-	-	-	-	-	-	-	-
Dayton NCORP	-	-	-	-	-	-	-	-	-	-	-
Essentia Hlth NCORP	-	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Ca Res Ctr LAPS	-	-	-	3	-	-	-	-	-	-	-
Georgia Cares MU NCORP	-	-	-	-	-	-	-	-	-	-	-
Georgia NCORP	-	-	1	-	-	-	-	-	-	-	-
Gulf South MU NCORP	-	-	3	-	-	-	-	-	-	-	-
Hawaii MU NCORP	-	-	-	-	-	-	-	-	-	-	-
Heartland Ca Res NCORP	-	-	-	-	-	-	1	-	-	-	-
Henry Ford Hosp	-	-	-	-	-	-	-	-	-	-	-
Houston Methodist Hosp	-	-	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCORP	-	4	6	-	2	-	-	-	-	-	-
Lahey Hosp and Med Ctr	-	-	2	-	-	-	-	-	-	-	-
Loma Linda U Med Ctr	-	-	-	-	-	-	-	-	-	-	-
Loyola U Med Ctr	-	-	1	2	-	-	-	-	-	-	1
Massachusetts Veterans ERIC	-	-	3	-	-	2	-	-	-	-	-
Med U South Carolina MU NCORP	-	-	-	-	-	-	-	-	-	-	-
Michigan Ca Res Consort NCORP	-	-	-	-	-	-	-	-	-	-	-
Moffitt CC	-	1	-	-	-	-	-	-	-	-	-
Montana Ca Consort NCORP	-	-	-	-	-	-	-	-	-	-	-
Mount Sinai Hosp	-	-	-	1	-	-	-	-	-	-	-
NCORP Carolinas (Prisma Hlth NCORP)	-	-	-	-	-	-	-	-	1	-	-
Nevada Ca Res Foundation NCORP	1	-	-	-	-	-	-	-	-	-	-

Lung Committee

Accrual from trial opening through 12/31/2022 by Institution and Study

	A171901	E4512	EA5163	EA5181	EA5182	EA5191	NRGCC003	NRGLU002	NRGLU005	NRGLU006	R1308
New Mexico MU NCORP	-	-	-	-	-	-	-	-	-	-	-
Northwell Hlth NCORP	-	-	-	-	-	-	-	-	-	-	-
Northwestern U LAPS	-	-	-	-	-	-	-	-	-	-	-
Oregon Hlth and Science U	-	-	-	-	-	-	-	-	-	-	-
Pacific Ca Res Consort NCORP	-	-	-	-	-	-	-	-	-	-	-
SCL Hlth Saint Joseph Hosp	-	-	-	-	-	-	-	-	-	-	-
Salem Hosp	-	-	-	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	-	-	-	-	-	-	-	-	-	-	-
Sutter Ca Res Consort	-	-	-	2	-	-	-	-	-	-	-
The Don and Sybil Harrington CC	-	-	-	-	-	-	-	-	-	-	-
James Graham Brown CC at U Louisville	-	-	-	-	-	-	-	-	-	-	-
UC Davis CCC LAPS	-	1	6	-	1	-	-	-	-	-	-
UC Irvine Hlth/Chao Family CCC	-	-	-	-	-	-	-	-	-	-	-
UC San Diego Moores CC	-	-	-	-	-	-	-	-	-	-	-
UPMC Hillman CC LAPS	-	-	-	-	-	-	-	-	-	-	-
USC Norris CCC LAPS	-	-	-	-	-	-	-	-	-	-	-
U Arkansas for Med Sciences	-	-	1	2	-	-	-	-	1	-	-
U Cincinnati CC-UC Med Ctr	-	1	-	-	1	-	-	-	-	-	-
U Colorado CC LAPS	-	2	-	-	-	1	-	-	1	-	-
U Kansas CC - MCA Rural MU NCORP	-	-	5	-	-	2	-	-	2	-	-
U Kentucky/Markey CC	-	-	-	-	-	-	-	-	-	-	-
U Michigan CCC LAPS	-	-	-	-	-	-	-	-	-	-	-
U Mississippi Med Ctr	-	-	-	-	-	-	-	-	-	-	-
U Oklahoma Hlth Sciences Ctr LAPS	-	-	-	1	-	-	-	-	-	-	-
U Rochester LAPS	-	-	2	15	-	-	4	-	1	-	-
U Texas HSC at San Antonio	-	-	2	-	-	-	-	-	-	-	-
U Texas MD Anderson CC LAPS	-	1	-	-	-	-	-	-	-	-	-
U Utah - Huntsman Ca Inst LAPS	-	-	1	-	-	-	-	-	-	-	-
Upstate Carolina NCORP	-	-	-	-	-	-	-	-	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	-	-	-	-	-	-	-	1	-	-	-
Western States Ca Res NCORP	-	-	-	-	-	-	-	-	-	-	-
William Beaumont Hosp-Royal Oak	-	-	-	-	-	-	-	-	-	-	-
Wisconsin NCORP	-	-	-	-	-	-	-	-	-	-	-
Yale U - Yale CC LAPS	-	4	11	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-	-
Total	1	17	56	52	6	7	5	2	13	2	1

Lung Committee

Concepts in Development

S1800E, "A Randomized Phase II Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Waqar and Li.

S1800F, "A Phase II Study of MK7684A (coformulation of Vibostolimab plus Pembrolizumab) in combination with Lenvatinib versus Standard of Care in Patients with Anti-PD-1 or Anti-PD-L1 Relapsed and Refractory Stage IV Non-Small Cell Lung Cancer (Lung-MAP Non-Match Sub-Study)." Drs. Massarelli and Li.

S2302 Pragmatica-Lung Trial presentation and discussion panel

**FRIDAY, MAY 12 | 4:50 – 5:25 PM PT
(IN THE LUNG COMMITTEE SESSION, FOLLOWING THE LIVINGSTON LECTURE)**

The S2302 Pragmatica-Lung Trial has generated wide interest as a phase III registration trial with a paradigm-changing, pragmatic design that significantly reduces enrollment barriers and data collection requirements. Attend this session to learn more about how the trial differs, its genesis, and what it means for the design and conduct of future NCTN trials.



**S2302 PROJECT PRAGMATICA LUNG TRIAL
A PRESENTATION BY STUDY CHAIR
KAREN L. RECKAMP, MD**

S2302 DISCUSSION PANEL WITH PANELISTS


Karen L. Reckamp, MD, associate director of Clinical Research and director of Medical Oncology in the Department of Medicine, Cedars-Sinai Cancer

Mary Redman, PhD, lead statistician, SWOG Lung Cancer Committee

Harpreet Singh, MD, director of the Division of Oncology 2, FDA

Shakun Malik, MD, head of Thoracic Cancer Therapeutics, NCI CTEP

Ellen V. Sigal, PhD, chairperson and founder, Friends of Cancer Research



A real-world clinical trial for patients whose non-small cell lung cancer has returned after immunotherapy